| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medical Oncology, Charing Cross & Westminister Medical School, St. Dunstan's Road, London, W6 8RF [R. C. C., M. Q., J. E.]; CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, SM2 5NG [B. P. H., I. R. J., L. J. G., G. A. P., R. M., M. J.]; and Department of Molecular Endocrinology, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ [M. D.], United Kingdom
Idoxifene, a novel antiestrogen with reduced estrogenic activity when compared to tamoxifen, has been given to 20 women with metastatic breast cancer, 19 of whom had received tamoxifen previously, in doses between 10–60 mg. Idoxifene had an initial half-life of 15 h and a terminal half-life of 23.3 days. At a maintenance dose of 20 mg, a mean steady-state level of 173.5 ng/ml was achieved. Significant falls in luteinizing hormone and follicle-stimulating hormone were seen, but the falls were not dose related. Idoxifene was well tolerated, with 11 patients complaining of mild symptoms similar to those seen with tamoxifen. Fourteen patients continued idoxifene therapy for 1–56 weeks; 4 patients showed stabilization of disease for 6–56 weeks and 2 patients showed a partial response.
1 To whom requests for reprints should be addressed.
Received 8/ 2/94. Accepted 1/ 4/95.
This article has been cited by other articles:
|
|
 |
|
  G. Arpino, M. Nair Krishnan, C. Doval Dinesh, V. J. Bardou, G. M. Clark, and R. M. Elledge Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer Ann. Onc., February 1, 2003; 14(2): 233 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Greenberger, T. Annable, K. I. Collins, B. S. Komm, C. R. Lyttle, C. P. Miller, P. G. Satyaswaroop, Y. Zhang, and P. Frost A New Antiestrogen, 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), Inhibits the Growth of Tamoxifen-sensitive and -resistant Tumors and Is Devoid of Uterotropic Effects in Mice and Rats Clin. Cancer Res., October 1, 2001; 7(10): 3166 - 3177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Lee, J. M. Schafer, K. Yao, G. England, R. M. O’Regan, A. D. L. Reyes, and V. C. Jordan Cross-Resistance of Triphenylethylene-type Antiestrogens but not ICI 182,780 in Tamoxifen-stimulated Breast Tumors Grown in Athymic Mice Clin. Cancer Res., December 1, 2000; 6(12): 4893 - 4899. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. K. Osborne and S. A. W. Fuqua Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use J. Clin. Oncol., September 17, 2000; 18(17): 3172 - 3186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dowsett, J. M. Dixon, K. Horgan, J. Salter, M. Hills, and E. Harvey Antiproliferative Effects of Idoxifene in a Placebo-controlled Trial in Primary Human Breast Cancer Clin. Cancer Res., June 1, 2000; 6(6): 2260 - 2267. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. D. Bischoff, R. A. Heyman, and W. W. Lamph Effect of the Retinoid X Receptor-Selective Ligand LGD1069 on Mammary Carcinoma After Tamoxifen Failure J Natl Cancer Inst, December 15, 1999; 91(24): 2118 - 2118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. D. Johnston, I. M. Boeddinghaus, S. Riddler, B. P. Haynes, I. R. Hardcastle, M. Rowlands, R. Grimshaw, M. Jarman, and M. Dowsett Idoxifene Antagonizes Estradiol-dependent MCF-7 Breast Cancer Xenograft Growth through Sustained Induction of Apoptosis Cancer Res., August 1, 1999; 59(15): 3646 - 3651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Osborne, A. Hewer, W. Davis, A. J. Strain, A. Keogh, I. R. Hardcastle, and D. H. Phillips Idoxifene derivatives are less reactive to DNA than tamoxifen derivatives, both chemically and in human and rat liver cells Carcinogenesis, February 1, 1999; 20(2): 293 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
